ReviewTherapeutics and clinical risk management2017

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Cristina Guarnera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.